title: A case report of fatal tumor lysis syndrome after chemotherapy in a pregnant patient with Burkitt's lymphoma.
abstract: A 35-year-old Japanese woman in the 24th week of gestation with bilateral breast enlargement was referred to hospital. She was diagnosed with Burkitt's lymphoma and admitted for detailed evaluation and treatment. Early delivery and subsequent chemotherapy was chosen after considering the gestational week, her general condition and the wishes of the patient and her husband. She gave birth to a male infant by cesarean section in the 25(th) week of gestation. It had been planned to begin high-dose chemotherapy, such as CODOX-M/IVAC, on day 7 of the puerperium; however, her general condition worsened and chemotherapy was therefore begun on day 2 after the birth. Eight hours after chemotherapy (cyclophosphamide, vincristine and doxorubicin), she developed cardiac arrest due to tumor lysis syndrome. Despite medical treatment, her bleeding tendency did not improve and she died of respiratory failure with alveolar bleeding five days after chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Niigata University Medical and Dental Hospital, Niigata, Japan. takehiro-s@med.niigata-u.ac.jp
authors.forename: Takehiro
authors.initials: T
authors.lastname: Serikawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Abe
authors.forename: Takahiro
authors.initials: T
authors.lastname: Minamikawa
authors.forename: Mina
authors.initials: M
authors.lastname: Itsukaichi
authors.forename: Kyoko
authors.initials: K
authors.lastname: Yamada
authors.forename: Tomoko
authors.initials: T
authors.lastname: Saito
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kaneko
authors.forename: Masaki
authors.initials: M
authors.lastname: Wada
authors.forename: Koichi
authors.initials: K
authors.lastname: Takakuwa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D002585:Cesarean Section; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D050498:Live Birth; D008297:Male; D049590:Postpartum Period; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents